Evidence map›Paper›PMID 40987742›Full record

ArticleBMJ open2025

Ventilator-associated pneumonia biomarker evaluation (VIBE) study: protocol for a prospective, observational, case-cohort study.

Owen Albin, Sudha Nadimidla, Louis Saravolatz, Anna Barker, Max Wayne, Danica Rockney, Raymond Jean, Andrew Nguyen, Murtaza Diwan, Virginia Pierce and 7 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Owen AlbinDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA oalbin@med.umich.edu.ORCID http://orcid.org/0000-0002-1659-4902
Sudha NadimidlaDepartment of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Louis SaravolatzDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Anna BarkerDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Max WayneDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Danica RockneyDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Raymond JeanDepartment of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Andrew NguyenDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Murtaza DiwanDepartment of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Virginia PierceDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Ashley RomanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jakob McSparronDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Robert DicksonDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Krishna RaoDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Lena M NapolitanoDepartment of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Richard WunderinkNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Keith KayeRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.

Funding

Personalizing Antimicrobial Use in Ventilator-Associated PneumoniaK23AI177689 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Owen Albin · 2024 to 2026
$583k
NIAID NIH HHS K23 AI177689
6 · The paper itself

Abstract

introductionCurrent guideline-recommended antibiotic treatment durations for ventilator-associated pneumonia (VAP) are largely standardised, with limited consideration of individual patient characteristics, pathogens or clinical context. This one-size-fits-all approach risks both overtreatment-promoting antimicrobial resistance and adverse drug events-as well as undertreatment, increasing the likelihood of pneumonia recurrence and sepsis-related complications. There is a critical need for VAP-specific biomarkers to enable individualised treatment strategies. The Ventilator-associated pneumonia Biomarker Evaluation (VIBE) study aims to identify a dynamic alveolar biomarker signature associated with treatment response, with the goal of informing personalised antibiotic duration in future clinical trials. METHODS AND ANALYSIS: VIBE is a prospective, observational, case-cohort study of 125 adult patients with VAP in Michigan Medicine University Hospital intensive care units. Study subjects will undergo non-bronchoscopic bronchoalveolar lavage on the day of VAP diagnosis (Day 1) and then on Days 3 and 5. Alveolar biomarkers (quantitative respiratory culture bioburden, alveolar neutrophil percentage and pathogen genomic load assessed via BioFire FilmArray polymerase chain reaction) will be assessed. An expert panel of intensivists, blinded to biomarker data, will adjudicate each patient's Day 10 outcome as VAP clinical cure (control) or treatment failure (case). Absolute biomarker levels and mean-fold changes in biomarker levels will be compared between groups. Data will be used to derive a composite temporal alveolar biomarker signature predictive of VAP treatment failure. ETHICS AND DISSEMINATION: Ethical approval was obtained from the University of Michigan Institutional Review Board (IRB #HUM00251780). Informed consent will be obtained from all study participants or their legally authorised representatives. Findings will be disseminated through peer-reviewed publications, conferences and feedback into clinical guidelines committees.

Indexed as

Anti-Bacterial AgentsPneumonia, Ventilator-AssociatedAdultBiomarkersBronchoalveolar Lavage FluidCase-Control StudiesHumansIntensive Care UnitsObservational Studies as TopicProspective StudiesResearch DesignAnti-Bacterial AgentsBiomarkersAdult intensive & critical careEpidemiologyMolecular diagnosticsRespiratory infectionsThoracic medicine

Identifiers

PMID40987742
PMCPMC12458857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.